D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Highlights from: The 2009 Annual Meeting of the American Society of Clinical Oncology Orlando, FL May 29-June 2, 2009
Journal ArticleDOI
2008 Highlights from: The IASLC-ESMO 1st European Lung Cancer Conference; Geneva, Switzerland; April 2008
Philip C. Mack,David R. Gandara +1 more
Journal ArticleDOI
P2.12-03 External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial
Laurent Dercle,David Gómez,Baiming Zhao,Karen Kelly,R. S. Herbst,Mary W. Redman,David R. Gandara,Lawrence H. Schwartz +7 more
TL;DR: In this article , the authors used artificial intelligence (AI) to enhance the role of CT imaging by taking advantage of previously unutilized information through the ability to identify imaging biomarkers through quantitative analysis that is objective, reproducible and rapidly obtainable.
Journal ArticleDOI
Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; May 30-June 3, 2008
Journal ArticleDOI
OA01.04 Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A
Fred R. Hirsch,X. Hua,M. Wu,Joel W. Neal,Haiying Cheng,Scott N. Gettinger,Lyudmilla Bazhenova,Vassiliki A. Papadimitrakopoulou,Hossein Borghaei,Philip C. Mack,Karen Kelly,Roy S. Herbst,David R. Gandara,Mary W. Redman,David Kozono +14 more
TL;DR: Lung-MAP is a master protocol for biomarker-driven trials in advanced NSCLC and the opportunity to evaluate TMB and related biomarkers by NGS and to determine associations with clinical outcomes was provided.